Ovarian Cancer Hemoscope Trial

N/AActive Not RecruitingNCT02811224

Scripps Translational Science Institute50 enrolled

Overview

This is a prospective, gold standard observational trial designed to enroll consecutive, consenting ovarian cancer patients for the purpose of determining sensitivity of an assay that detects circulating tumor DNA. This observational pilot trial will also be used to examine the genetic variants/mutations present in the tumor tissue DNA.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Ovarian Neoplasms

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: Case Group * Patients with ovarian cancer undergoing surgery (all stages) * Over 18 years old Control Group * Patients with a benign gynecological condition undergoing surgery * Over 18 years old Exclusion Criteria: * Previous cancer diagnosis (all) * Radiation therapy before surgical treatment * Bone marrow transplant * Chemotherapy before surgical treatment * Invasive procedure resulting in damage to tissue (e.g., surgery, biopsy, thermal ablation) in the 7 days prior to baseline (pre-surgical) blood collection

Outcomes

Primary Outcomes

Sensitivity of an assay that detects circulating tumor DNA

Time frame: 3 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.